Page last updated: 2024-12-08

1-Acetamidocyclopentanecarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-Acetamidocyclopentanecarboxylic acid, also known as **ACPC**, is a **synthetic amino acid** that is **not naturally occurring**. It is a derivative of **cyclopentanecarboxylic acid** with an **acetamide group** attached at the **1-position**.

**Importance in Research:**

ACPC has gained significant attention in research due to its potential in various fields:

* **Drug Development:**
* **Anti-cancer properties:** ACPC has been shown to exhibit promising anti-cancer activity in preclinical studies. It can interfere with **cell proliferation** and **tumor growth**, potentially by inhibiting the **mTOR pathway** involved in cell growth and survival.
* **Neuroprotective effects:** ACPC has also been investigated for its potential **neuroprotective** properties, potentially by reducing **excitotoxicity** and **inflammation** in the brain.
* **Chemical Synthesis:**
* **Chiral building block:** ACPC's **stereochemical structure** makes it a valuable **chiral building block** in organic synthesis. It can be utilized to construct various biologically active molecules with specific chirality.
* **Analytical Chemistry:**
* **Chromatographic standards:** ACPC can be used as a **chromatographic standard** for analyzing other similar compounds, particularly in **pharmaceutical analysis**.

**Current Research:**

Ongoing research focuses on:

* Understanding the detailed mechanism of action of ACPC in different biological systems.
* Evaluating its efficacy and safety in preclinical and clinical trials for various disease indications.
* Exploring the potential of ACPC as a building block for developing novel drugs and other useful compounds.

**Note:**

While ACPC shows promise in research, it is still under investigation. Further research is needed to determine its potential therapeutic applications and safety profile.

Cross-References

ID SourceID
PubMed CID229296
CHEMBL ID1416412
CHEBI ID195588
SCHEMBL ID1573844

Synonyms (27)

Synonym
mls000738007 ,
4854-46-0
nsc-22847
nsc22847
smr000393684
1-acetamidocyclopentanecarboxylic acid
1-(acetylamino)cyclopentanecarboxylic acid
1-acetamidocyclopentane-1-carboxylic acid
CHEBI:195588
AKOS005362740
NCGC00246920-01
EN300-73011
cyclopentanecarboxylicacid, 1-(acetylamino)-
cyclopentanecarboxylic acid, 1-acetamido-
1-acetylaminocyclopentanecarboxylic acid
niosh/gy2610000
cb 1709
GY26100000
HMS2753O23
SCHEMBL1573844
CHEMBL1416412
A1-00925
DTXSID20281738
Z234898151
FT-0722305
CS-0217294
1-acetamidocyclopentanecarboxylicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
IDH1Homo sapiens (human)Potency18.35640.005210.865235.4813AID686970
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency5.01190.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]